+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition



Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition



Clinical Cancer Research 24(1): 84-94



Purpose: Despite intense research, treatment options for patients with mesothelioma are limited and offer only modest survival advantage. We screened a large panel of compounds in multiple mesothelioma models and correlated sensitivity with a range of molecular features to detect biomarkers of drug response.Experimental design: We utilized a high-throughput chemical inhibitor screen in a panel of 889 cancer cell lines, including both immortalized and primary early-passage mesothelioma lines, alongside comprehensive molecular characterization using Illumina whole-exome sequencing, copy-number analysis and Affymetrix array whole transcriptome profiling. Subsequent validation was done using functional assays such as siRNA silencing and mesothelioma mouse xenograft models.Results: A subgroup of immortalized and primary MPM lines appeared highly sensitive to FGFR inhibition. None of these lines harbored genomic alterations of FGFR family members, but rather BAP1 protein loss was associated with enhanced sensitivity to FGFR inhibition. This was confirmed in an MPM mouse xenograft model and by BAP1 knockdown and overexpression in cell line models. Gene expression analyses revealed an association between BAP1 loss and increased expression of the receptors FGFR1/3 and ligands FGF9/18. BAP1 loss was associated with activation of MAPK signaling. These associations were confirmed in a cohort of MPM patient samples.Conclusions: A subgroup of mesotheliomas cell lines harbor sensitivity to FGFR inhibition. BAP1 protein loss enriches for this subgroup and could serve as a potential biomarker to select patients for FGFR inhibitor treatment. These data identify a clinically relevant MPM subgroup for consideration of FGFR therapeutics in future clinical studies. Clin Cancer Res; 24(1); 84-94. ©2017 AACR.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 059537185

Download citation: RISBibTeXText

PMID: 29061644

DOI: 10.1158/1078-0432.ccr-17-1172


Related references

Comprehensive pharmacogenomic profiling of human papillomavirus-positive and -negative squamous cell carcinoma identifies sensitivity to aurora kinase inhibition in KMT2D mutants. Cancer Letters 431: 64-72, 2018

Protein profiling of pleural effusions to identify malignant pleural mesothelioma using SELDI-TOF MS. Technology in Cancer Research and Treatment 8(5): 323-332, 2009

Photomicrographs of a pleural biopsy specimen, showing malignant mesothelioma and necrosis--malignant pleural mesothelioma in a patient with sarcoidosis. Nihon Kyobu Shikkan Gakkai Zasshi 35(6): 687-691, 1997

Malignant pleural mesothelioma: a comprehensive review. Cancer Control 13(4): 255-263, 2006

Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. Journal of Clinical Oncology 25(36): 5770-5776, 2007

Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma. Jci Insight 3(7):, 2018

Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest 125(5): 1843-1852, 2004

A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma. Journal of Molecular Diagnostics 12(6): 771-779, 2010

The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review. Anticancer Research 33(9): 3553-3561, 2013

Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition. Clinical Cancer Research 20(5): 1323-1334, 2014

Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA. Journal of Clinical Pathology 66(10): 854-861, 2013

Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers. Biomarkers 21(6): 551-561, 2016

Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions. Bmc Cancer 14: 709, 2014

Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma. Molecular & Cellular Proteomics 13(3): 701-715, 2014

Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma. Journal of Clinical Pathology 70(2): 179-182, 2017